Tumor Microenvironment, Immunity and Tumor Immune Escape Mechanisms: Emerging Treatment Strategies for Fighting Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 547
Special Issue Editor
Interests: tumor heterogeneity; hypoxia; immune evasion; tumor microenvironment; resistance; immunotherapy; biomarkers, NK cells; CTL; cellular plasticity; EMT; prostate cancer; urology; lung cancer; renal cancer; melanoma
Special Issue Information
Dear Colleagues,
Evading the immune system is one of the hallmarks of cancer. Tumors represent a complex ecosystem infiltrated by immune cell populations and diverse stromal cell types evolving in a special physicochemical milieu and various stress conditions. Tumors escape anti-tumor immunity through cell-intrinsic routes and the assembly of an immunosuppressive tumor microenvironment (TME). Recent cancer immunotherapies have revolutionized the management of many patients with aggressive cancers. This also reveals the potential of boosting pre-existing immunological features in some patients. Nonetheless, a significant proportion of patients remain refractory or rapidly relapse, and the factors involved in resistant and relapsing diseases are still poorly understood. This Special Issue will focus on novel mechanisms involving the TME, malignant cells and points of crosstalk that might be key determinants in immune escape and immunotherapeutic resistance. It will also highlight novel methods and compounds developed targeting the TME and its metabolism to optimize immunotherapy-based interventions and widen the therapeutic options for patients.
Dr. Stephane Terry
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor microenvironment
- tumor heterogeneity
- tumor immunity
- tumor resistance
- immune evasion
- immunotherapy
- hypoxia
- targeted therapy
- immuno-oncology
- combination therapy
- drug development
